Q3155443 (Q3155443): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Created claim: summary (P836): Thyroid function parameters, especially in pregnant women, are subject to significant intra- and intersubjective variability that hinders their clinical interpretation and standardisation of diagnostic and therapeutic criteria. Objective: Generate a personalised and predictive score of obstetric-perinatal complications and concentration of fetal neurodevelopment biomarkers based on the determination of maternal first trimester TSH corrected by...) |
||||||||||||||
| Property / summary | |||||||||||||||
Thyroid function parameters, especially in pregnant women, are subject to significant intra- and intersubjective variability that hinders their clinical interpretation and standardisation of diagnostic and therapeutic criteria. Objective: Generate a personalised and predictive score of obstetric-perinatal complications and concentration of fetal neurodevelopment biomarkers based on the determination of maternal first trimester TSH corrected by the most relevant factors that determine the variability of this parameter. Methodology: (a): a1) TSH study in the first trimester based on cluster sampling in 400 pregnant women and genesis of a nomogram using multiple regression analysis; analysis of internal/external validity in the determination of free T4 during gestation. b) Fetal cord blood measurement of neurodevelopment biomarkers (brain-derived neurotrophic factor (BDNF), lysophosphatidic acid (LPA), growth-derived neurotrophic factor (GDNF)); evaluation of obstetric or perinatal complications. Given that there is no consensus among the different scientific societies on the need for universal screening of thyroid dysfunction during the first trimester and that a universally accepted thyrotropin cut-off point has not been established to initiate treatment with thyroxine in pregnant women, the results of the project will establish a personalised TSH cut-off point that allows therapeutic decision-making. (English) | |||||||||||||||
| Property / summary: Thyroid function parameters, especially in pregnant women, are subject to significant intra- and intersubjective variability that hinders their clinical interpretation and standardisation of diagnostic and therapeutic criteria. Objective: Generate a personalised and predictive score of obstetric-perinatal complications and concentration of fetal neurodevelopment biomarkers based on the determination of maternal first trimester TSH corrected by the most relevant factors that determine the variability of this parameter. Methodology: (a): a1) TSH study in the first trimester based on cluster sampling in 400 pregnant women and genesis of a nomogram using multiple regression analysis; analysis of internal/external validity in the determination of free T4 during gestation. b) Fetal cord blood measurement of neurodevelopment biomarkers (brain-derived neurotrophic factor (BDNF), lysophosphatidic acid (LPA), growth-derived neurotrophic factor (GDNF)); evaluation of obstetric or perinatal complications. Given that there is no consensus among the different scientific societies on the need for universal screening of thyroid dysfunction during the first trimester and that a universally accepted thyrotropin cut-off point has not been established to initiate treatment with thyroxine in pregnant women, the results of the project will establish a personalised TSH cut-off point that allows therapeutic decision-making. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: Thyroid function parameters, especially in pregnant women, are subject to significant intra- and intersubjective variability that hinders their clinical interpretation and standardisation of diagnostic and therapeutic criteria. Objective: Generate a personalised and predictive score of obstetric-perinatal complications and concentration of fetal neurodevelopment biomarkers based on the determination of maternal first trimester TSH corrected by the most relevant factors that determine the variability of this parameter. Methodology: (a): a1) TSH study in the first trimester based on cluster sampling in 400 pregnant women and genesis of a nomogram using multiple regression analysis; analysis of internal/external validity in the determination of free T4 during gestation. b) Fetal cord blood measurement of neurodevelopment biomarkers (brain-derived neurotrophic factor (BDNF), lysophosphatidic acid (LPA), growth-derived neurotrophic factor (GDNF)); evaluation of obstetric or perinatal complications. Given that there is no consensus among the different scientific societies on the need for universal screening of thyroid dysfunction during the first trimester and that a universally accepted thyrotropin cut-off point has not been established to initiate treatment with thyroxine in pregnant women, the results of the project will establish a personalised TSH cut-off point that allows therapeutic decision-making. (English) / qualifier | |||||||||||||||
point in time: 12 October 2021
| |||||||||||||||
Revision as of 15:00, 12 October 2021
Project Q3155443 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3155443 in Spain |
Statements
71,500.0 Euro
0 references
143,000.0 Euro
0 references
50.0 percent
0 references
1 January 2016
0 references
31 March 2020
0 references
FUNDACION INSTITUTO DE INVESTIGACION EN CIENCIAS DE LA SALUD GERMANS TRIAS I PUJOL
0 references
41°26'57.66"N, 2°14'53.70"E
0 references
08015
0 references
Los parámetros de función tiroidea, especialmente en la mujer gestante, están sujetos a una importante variabilidad intra e intersujeto que dificulta su interpretación clínica y la estandarización de criterios diagnósticos y terapéuticos. Objetivo: Generar un score personalizado y predictivo de complicaciones obstétrico-perinatales y de la concentración de biomarcadores de neurodesarrollo fetal basado en la determinación de TSH materna de primer trimestre corregida por los factores más relevantes que determinan la variabilidad de este parámetro. Metodología: a): a1) Estudio de TSH en primer trimestre a partir de un muestreo por conglomerados en 400 gestantes y génesis de un nomograma mediante análisis de regresión múltiple.; a2) Análisis de la validez interna/externa en la determinación de T4 libre durante la gestación. b) medición en sangre de cordón fetal de biomarcadores de neurodesarrollo (brain-derived neurotrophic factor (BDNF), ácido lisofosfatídico (LPA), growth-derived neurotrophic factor (GDNF)); c) evaluación de complicaciones obstétricas y/o perinatales. Dado que no existe un consenso entre las diferentes sociedades científicas sobre la necesidad de cribado universal de la disfunción tiroidea durante el primer trimestre y que no se ha establecido un punto de corte de tirotropina TSH universalmente aceptado para iniciar el tratamiento con tiroxina en gestantes, los resultados del proyecto permitirán establecer un punto de corte personalizado de TSH que permita la toma de decisión terapéutica. (Spanish)
0 references
Thyroid function parameters, especially in pregnant women, are subject to significant intra- and intersubjective variability that hinders their clinical interpretation and standardisation of diagnostic and therapeutic criteria. Objective: Generate a personalised and predictive score of obstetric-perinatal complications and concentration of fetal neurodevelopment biomarkers based on the determination of maternal first trimester TSH corrected by the most relevant factors that determine the variability of this parameter. Methodology: (a): a1) TSH study in the first trimester based on cluster sampling in 400 pregnant women and genesis of a nomogram using multiple regression analysis; analysis of internal/external validity in the determination of free T4 during gestation. b) Fetal cord blood measurement of neurodevelopment biomarkers (brain-derived neurotrophic factor (BDNF), lysophosphatidic acid (LPA), growth-derived neurotrophic factor (GDNF)); evaluation of obstetric or perinatal complications. Given that there is no consensus among the different scientific societies on the need for universal screening of thyroid dysfunction during the first trimester and that a universally accepted thyrotropin cut-off point has not been established to initiate treatment with thyroxine in pregnant women, the results of the project will establish a personalised TSH cut-off point that allows therapeutic decision-making. (English)
12 October 2021
0 references
Badalona
0 references
Identifiers
PI15_02192
0 references